At the recent ASCO conference, Infinity Pharmaceuticals posted solid efficacy data for its non-Hodgkin's lymphoma drug, but shares cratered, closing down 39%. The problem is that Infinity's drug, while promising, doesn't exist in a vacuum and will see competition from two of health care's biggest players.

In this video, health-care analyst David Williamson takes a closer look at the three promising blood cancer drugs that caused some big stock movements earlier this month.